Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 752-756

  Ravandi, Farhad ^a   Kantarjian, Hagop ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   O'Brien, Susan ^a   Koller, Charles ^a   Pierce, Sherry ^a   Brandt, Mark ^a   Kennedy, Deborah ^b   Cortes, Jorge ^a   Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CEPHALON INC   (United States)

Author keywords

Acute myeloid leukemia; FLT3 mutations; Outcome; Relapse

Indexed keywords

CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 11; TIOGUANINE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DISEASE ASSOCIATION; DISEASE DURATION; GENE DUPLICATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952092621     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.001     Document Type: Article

References (34)

1. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100(5):1532-1542.
2. Brasel K., Escobar S., Anderberg R., et al. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995, 9(July (7)):1212-1218.
3. Drexler H.G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996, 10(April (4)):588-599.
4. Turner A.M., Lin N.L., Issarachai S., et al. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996, 88(November (9)):3383-3390.
5. Birg F., Courcoul M., Rosnet O., et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992, 80(November (10)):2584-2593.
6. Carow C.E., Levenstein M., Kaufmann S.H., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996, 87(February (3)):1089-1096.
7. Stacchini A., Fubini L., Severino A., et al. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia 1996, 10(October (10)):1584-1591.
8. Levis M., Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003, 17(September (9)):1738-1752.
9. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10(December (12)):1911-1918.
10. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(June (12)):4326-4335.
11. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97(April (8)):2434-2439.
12. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000, 111(October (1)):190-195.
13. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001, 113(June (4)):983-988.
14. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100(December (13)):4372-4380.
15. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(September (6)):1752-1759.
16. Meshinchi S., Stirewalt D.L., Alonzo T.A., et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003, 102(August (4)):1474-1479.
17. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93(May (9)):3074-3080.
18. Mead A.J., Linch D.C., Hills R.K., et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110(August (4)):1262-1270.
19. Whitman S.P., Ruppert A.S., Radmacher M.D., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111(February (3)):1552-1559.
20. Mead A.J., Gale R.E., Hills R.K., et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008, 112(July (2)):444-445. author reply 445.
21. Kiyoi H., Ohno R., Ueda R., et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21(April (16)):2555-2563.
22. Levis M., Tse K.F., Smith B.D., et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001, 98(August (3)):885-887.
23. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103(May (10)):3669-3676.
24. Stone R.M., DeAngelo D.J., Klimek V., et al. Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2004.
25. DeAngelo D.J., Stone R.M., Heaney M.L., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108(December (12)):3674-3681.
26. Mori S., Cortes J., Kantarjian H., et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008, 49(December (12)):2246-2255.
27. Metzelder S., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113(June (26)):6567-6571.
28. Levis M., Ravandi F., Wang E., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse 2009.
29. Kern W., Estey E.H. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006, 107(July (1)):116-124.
30. Estey E. Treatment of refractory AML. Leukemia 1996, 10(June (6)):932-936.
31. Rytting M., Verstovsek S., Garcia-Manero G., et al. Intensively timed induction (ITI) chemotherapy in adults with acute myelogenous leukemia (AML). Blood 2007, 110. Abstract 1851.
32. Beran M., Luthra R., Kantarjian H., et al. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res. 2004, 28(June (6)):547-550.
33. Lin P., Jones D., Medeiros L.J., et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 2006, 126(October (4)):530-533.
34. Kottaridis P.D., Gale R.E., Langabeer S.E., et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100(October (7)):2393-2398.